{"id":4086,"date":"2017-12-28T15:24:02","date_gmt":"2017-12-28T15:24:02","guid":{"rendered":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=4086"},"modified":"2017-12-28T15:24:02","modified_gmt":"2017-12-28T15:24:02","slug":"antikoagulatorische-tripel-therapie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/","title":{"rendered":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance"},"content":{"rendered":"<p>AMB 2017, 51, 94\u00a0 Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance &nbsp; Fazit: Die duale antithrombotische Therapie (orales Antikoagulans plus einfache Hemmung der Thrombozytenfunktion) hat bei Patienten mit Vorhofflimmern und neuimplantiertem koronarem Stent eine g\u00fcnstigere Nutzen-Risiko-Relation als die klassische Dreifach-Therapie (orales Antikoagulans plus doppelte Hemmung der Thrombozytenfunktion). Eine \u00dcberlegenheit der NOAK gegen\u00fcber Vitamin-K-Antagonisten l\u00e4sst [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2017, 51, 94\u00a0 Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance &nbsp; Fazit: Die duale antithrombotische Therapie (orales Antikoagulans plus einfache Hemmung der Thrombozytenfunktion) hat bei Patienten mit Vorhofflimmern und neuimplantiertem koronarem Stent eine g\u00fcnstigere Nutzen-Risiko-Relation als die klassische Dreifach-Therapie (orales Antikoagulans plus doppelte Hemmung der Thrombozytenfunktion). Eine \u00dcberlegenheit der NOAK gegen\u00fcber Vitamin-K-Antagonisten l\u00e4sst [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[200,128,66,67,2195,129,139,69,2776,121,61,1457,1458,527,528,87,85,88,2777,122,60,324,203,106,146,2607,204,205],"class_list":["post-4086","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acetylsalicylsaeure","tag-antikoagulanzien","tag-apoplektischer-insult","tag-ass","tag-azetylsalizylsaeure","tag-clopidogrel","tag-dabigatran","tag-deeskalation","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-re-dual-pci-studie","tag-rhythmusstoerungen","tag-schlaganfall","tag-stent","tag-thromboembolie","tag-thrombozytenaggregationshemmer","tag-ticagrelor","tag-tripel-therapie","tag-vorhofflimmern","tag-warfarin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"AMB 2017, 51, 94\u00a0 Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance &nbsp; Fazit: Die duale antithrombotische Therapie (orales Antikoagulans plus einfache Hemmung der Thrombozytenfunktion) hat bei Patienten mit Vorhofflimmern und neuimplantiertem koronarem Stent eine g\u00fcnstigere Nutzen-Risiko-Relation als die klassische Dreifach-Therapie (orales Antikoagulans plus doppelte Hemmung der Thrombozytenfunktion). Eine \u00dcberlegenheit der NOAK gegen\u00fcber Vitamin-K-Antagonisten l\u00e4sst [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-28T15:24:02+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance\",\"datePublished\":\"2017-12-28T15:24:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Absolute Arrhythmie\",\"Acetylsalicyls\u00e4ure\",\"Antikoagulanzien\",\"Apoplektischer Insult\",\"ASS\",\"Azetylsalizyls\u00e4ure\",\"Clopidogrel\",\"Dabigatran\",\"Deeskalation\",\"Herzrhythmusst\u00f6rungen\",\"Hirninfarkt\",\"Neue orale Antikoagulanzien\",\"NOAK\",\"PCI\",\"Perkutane Koronarintervention\",\"Perkutane transluminale koronare Angioplastie\",\"Prasugrel\",\"PTCA\",\"RE-DUAL-PCI-Studie\",\"Rhythmusst\u00f6rungen\",\"Schlaganfall\",\"Stent\",\"Thromboembolie\",\"Thrombozytenaggregationshemmer\",\"Ticagrelor\",\"Tripel-Therapie\",\"Vorhofflimmern\",\"Warfarin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/\",\"name\":\"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2017-12-28T15:24:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/antikoagulatorische-tripel-therapie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/","og_locale":"de_DE","og_type":"article","og_title":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief","og_description":"AMB 2017, 51, 94\u00a0 Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance &nbsp; Fazit: Die duale antithrombotische Therapie (orales Antikoagulans plus einfache Hemmung der Thrombozytenfunktion) hat bei Patienten mit Vorhofflimmern und neuimplantiertem koronarem Stent eine g\u00fcnstigere Nutzen-Risiko-Relation als die klassische Dreifach-Therapie (orales Antikoagulans plus doppelte Hemmung der Thrombozytenfunktion). Eine \u00dcberlegenheit der NOAK gegen\u00fcber Vitamin-K-Antagonisten l\u00e4sst [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2017-12-28T15:24:02+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance","datePublished":"2017-12-28T15:24:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/"},"wordCount":310,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Absolute Arrhythmie","Acetylsalicyls\u00e4ure","Antikoagulanzien","Apoplektischer Insult","ASS","Azetylsalizyls\u00e4ure","Clopidogrel","Dabigatran","Deeskalation","Herzrhythmusst\u00f6rungen","Hirninfarkt","Neue orale Antikoagulanzien","NOAK","PCI","Perkutane Koronarintervention","Perkutane transluminale koronare Angioplastie","Prasugrel","PTCA","RE-DUAL-PCI-Studie","Rhythmusst\u00f6rungen","Schlaganfall","Stent","Thromboembolie","Thrombozytenaggregationshemmer","Ticagrelor","Tripel-Therapie","Vorhofflimmern","Warfarin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/","name":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2017-12-28T15:24:02+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/antikoagulatorische-tripel-therapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=4086"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4086\/revisions"}],"predecessor-version":[{"id":4087,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4086\/revisions\/4087"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=4086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=4086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=4086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}